权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core B: Biospecimen and Pathology Resources Core

核心 B：生物样本和病理学资源核心

基本信息

批准号：
10708846
负责人：
Payal Kapur
金额：
$ 35.72万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10708846
关键词：
Academia Address Adult Advisory Committees Animal Model BRAF gene Basic Science Benchmarking Biological Assay Biological Specimen Banks Black race Blood CLIA certified Cancer Biology Cell Culture Techniques Cell Line Clinic Clinical Clinical Data Clinical Trials Collaborations Communication Communities Complement Comprehensive Cancer Center Cryopreserved Tissue DNA DNA copy number Dana-Farber Cancer Institute Data Development Dimethyl Sulfoxide Evaluation FDA approved Fostering Freezing Gene Expression Generations Genetic Genitourinary system Genomics Goals Hispanic Histologic Histology Human Image Analysis Immunoassay Immunohistochemistry Implant In Situ Hybridization Industry Infrastructure Institution Journals Kidney Kidney Neoplasms Laboratories Letters Link Malignant Neoplasms Medical center Metabolic Metabolism Modeling Molecular Mus Mutation National Cancer Institute National Comprehensive Cancer Network Nature Neoplasm Metastasis Nutrient Oncology Paraffin Embedding Pathologic Pathologist Pathology Pathway interactions Patient Care Patients Pharmaceutical Preparations Primary Neoplasm Principal Investigator Protocols documentation Publishing Quality Control RNA Radiation Renal Cell Carcinoma Renal Mass Renal carcinoma Research Research Personnel Resources SNP array Sampling Services Small Interfering RNA Specimen Stable Isotope Labeling Standardization Stimulator of Interferon Genes Testing Texas Therapeutic Tissue Banks Tissue Microarray Tissue Preservation Tissue Procurements Tissues Tracer Transgenic Organisms Translational Research Tropism Tumor Bank Tumor Cell Line Tumor Markers Universities Validation assay development biobank brca gene cancer cell clinical practice cohort digital pathology drug sensitivity drug testing ethnic diversity exome sequencing experience federated learning human model improved in vivo innovation interdisciplinary approach knockout animal laser capture microdissection member patient derived xenograft model personalized diagnostics personalized medicine pre-clinical precision medicine preservation programmed cell death ligand 1 programs racial diversity radiotracer rare condition repository stem tissue processing tissue resource transcriptome sequencing translational goal tumor whole slide imaging

项目摘要

Project Summary The aims of the Biospecimen and Pathology Resources (BPR) Core (Core B) are to facilitate the storage and distribution of comprehensively annotated, high-quality biospecimens and their derivatives, and to provide professional and technical pathology services to the principal investigators and collaborators of our SPORE and Kidney Cancer Program. All three SPORE projects utilize Core B, which is critical to achieving their aims. It is an indispensable component of our SPORE and leverages and expands (without duplicating) existing pathology resources in our National Cancer Institute (NCI)-designated Simmons Comprehensive Cancer Center. We deliver basic histology, immunohistochemistry (IHC), in situ hybridization (ISH), tissue microarrays, whole slide imaging, image analysis, and laser-capture microdissection services, and make available unique cancer tissue derivatives such as primary cancer cell cultures and cell lines, cryopreserved tissues, DNA, RNA, and patient- derived xenografts (PDX or tumorgrafts, TG). These efforts are complemented by several national initiatives led by the Core. This Core provides expertise in histomorphologic evaluation of human kidney tumors, human tumorgrafts in mice, kidney tumors in transgenic and knockout animal models, and in the interpretation of IHC and ISH and multiplex immunoassays. The BPR Core develops IHC and molecular assays and has experience in the deployment of CLIA-certified laboratory tests, such as our PD-L1 IHC. The BPR Core currently has fresh- frozen renal tumor and paired-normal kidney (or blood) tissues for >1,700 racially and ethnically diverse patients; a unique live-tissue repository of >1,900 kidney tumor tissues preserved viable in DMSO for mechanistic studies to address questions arising from genomic and other studies of inert tissues; >200 independent TG lines; 47 primary tumor cell lines representing a wide variety of tumors; and integrated genomic analyses (exome sequencing, RNA-Seq and SNP arrays) of >500 RCC patients. Specimen data is linked to the institutional tissue bank, and to comprehensive patient clinical data through Kidney Cancer Explorer (Core C). The BPR Core provides routine quality control for SPORE investigators to ensure that the tissues are optimal, and several of our protocols have been published in Nature Protocols and serve as benchmarks in the fields of tissue processing for integrated genomic analyses and TG utilization for preclinical drug testing. Our repository has had significant utilization, with >1,000 samples having been shipped to collaborators both internally, as well as externally. TGs have been extensively utilized to evaluate RCC drug sensitivity, study radiation responsiveness, explore tumor biomarkers, understand cancer biology (including rare syndromes), and dissect metabolic derangements in RCC. Studies with these tissues have been published in high-impact journals such as Nature Genetics, Nature Communications, and Lancet Oncology. Our Core promotes flourishing collaborations among our SPORE investigators, investigators from other SPOREs, and other investigators in academia and industry.

项目总结